We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11,786.00 | 11,818.00 | 11,824.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8406 | 30.78 | 182.75B |
From Feb 2020 to Feb 2025
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) Wednesday reported positive trial results for Lynparza, drug used for the treatment of ovarian cancer.
The pharmaceutical company said phase III SOLO-2 trial of Lynparza tablets, 300 milligrams twice daily, demonstrated a clinically-meaningful and statistically-significant improvement of progression-free survival among patients.
"We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine," said AstraZeneca's Chief Medical Officer and Executive Vice President for Medicines Development Sean Bohen.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 26, 2016 02:38 ET (06:38 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
